Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics, Inc. reported that investment entity ForDyne B.V., which is associated with director Dirk Kersten, sold a total of 337,248 shares of common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
ForDyne sold 211,974 shares at a weighted average price of $20.2916 on April 17, 2026 and 125,274 shares at a weighted average price of $20.0672 on April 20, 2026, across price ranges disclosed in the footnotes. Following these sales, entities linked to ForDyne continued to hold 4,207,525 shares indirectly, and Kersten disclaims beneficial ownership beyond his pecuniary interest.
Dyne Therapeutics, Inc. director-associated entity ForDyne B.V. reported open-market sales of a total of 99,613 shares of common stock over two days. The trades, made on April 15–16, 2026, were executed under a Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025.
Shares were sold at weighted average prices of $20.2718 for 81,840 shares, $20.0575 for 6,657 shares, and $21.1039 for 11,116 shares, across specified intraday price ranges. Following these sales, entities associated with ForDyne continued to hold 4,544,773 shares of Dyne Therapeutics common stock indirectly. The reporting person disclaims beneficial ownership beyond any pecuniary interest.
Dyne Therapeutics, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 5, 2026 to elect three Class III directors, hold an advisory say-on-pay vote, and seek approval of two charter amendments including an increase in authorized common shares from 200,000,000 to 400,000,000. The meeting will also consider officer exculpation and ratify Deloitte & Touche LLP as independent auditors.
Stockholders of record as of April 7, 2026 may vote; shares outstanding on that date were 165,219,501. The board recommends voting FOR each proposal. Attendance is online at www.proxydocs.com/DYN and registration is required in advance.
Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 5,727 shares of common stock at a weighted average price of $18.64 per share. According to the disclosure, these shares were sold automatically to satisfy tax withholding obligations tied to restricted stock units that vested on March 31, 2025, under a pre-established agreement treated as a binding contract consistent with Rule 10b5-1. Following the transaction, Erick holds 125,373 shares, including 114,575 unvested restricted stock units, indicating this was a routine, tax-driven event rather than a discretionary trade.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of 2,000 shares of common stock. The shares were bought at a weighted average price of $17.08 per share on this transaction date, with individual trade prices ranging from $17.06 to $17.10. Following this purchase, Posner directly holds 15,500 Dyne Therapeutics shares.